U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07645248) titled 'A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)' on June 08.

Brief Summary: This study aims to generate additional safety data on the propellant component of the reformulated product by comparing metered dose inhaler (MDIs) containing HFA-152a (test) with HFA-134a (reference).

Study Start Date: Sept. 15, 2026

Study Type: INTERVENTIONAL

Condition: Asthma

Intervention: DRUG: HFA-152a

HFA-152a will be administered.

DRUG: HFA-134a

HFA-134a will be administered.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: GlaxoSmithKline ...